Effects of Acupuncture Stimulation on Systemic Inflammation

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

60 participants

Study Classification

INTERVENTIONAL

Study Start Date

2016-11-30

Study Completion Date

2017-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

60 ASA physical status I or II patients, aged 18-75 years old , scheduled for elective video-assisted thoracoscopic lobectomy surgery,will be randomized into 2 groups,with 30 patients in each group: 1. control group and 2. treatment group. Patients in treatment group will receive transcutaneous electrical acupoint stimulation(TEAS) during the surgery and at 6h and 24h after surgery. Patients in the control group received only TIVA general anesthesia and sham electrical stimulation. Serum from patients of both groups will be collected at before surgery, 1h and 25h after surgery, respectively. Serum levels of TNF-alpha, IL-1 beta, CXCL8, IFN gamma and IL-4 at different time points will be measured and compared between the two groups.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Acupuncture Research on Lung Cancer Patients With Cancer Related Fatigue（CRF）

NCT01881516

Lung Cancer Cancer Related Fatigue

UNKNOWN PHASE2

Transcutaneous Electrical Acupoint Stimulation for Non-small Cell Lung Cancer Patients

NCT02663492

Non-Small Cell Lung Cancer Lung Cancer

UNKNOWN NA

Acupuncture for the Immune System in Radiation Cancer Patients

NCT01422928

Gastrointestinal Neoplasms Urogenital Neoplasms

WITHDRAWN PHASE3

Acupuncture as the Therapeutic Modalities of Acute Toxicity in the Radiotherapy of Head and Neck Tumors

NCT03751566

Malignant Tumor of Soft Tissue of Head, Face and Neck

RECRUITING NA

Feasibility, Safety, and Efficacy of Stereotactic MRI-Guided Adaptive Radiation Therapy (SMART) for Central Lung Tumors

NCT05609331

Lung Cancer

TERMINATED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

60 ASA physical status I or II patients, aged 18-75 years old , scheduled for elective video-assisted thoracoscopic lobectomy surgery,will be randomized into 2 groups,with 30 patients in each group: 1. control group, who will receive total intravenous anesthesia(TIVA) and sham stimulation; and 2. treatment group, who will receive (TIVA) and transcutaneous electrical acupoint stimulation(TEAS). Since 30 min before induction of anesthesia, patients in treatment group will be stimulated at the 4 acupoints , Houxi、Zhigou、Neiguan and Hegu on both sides by Han's Acupoint Nerve Stimulator(HANS) until the end of the operation. At 6h and 24h after surgery, patients in treatment group will receive TEAS again, for 30 min each time.The frequency was 2/100Hz,the stimulate intensity was the maximum current that could be tolerated when the patients were awake.The control group received only TIVA general anesthesia and sham electrical stimulation.Serum from patients of both groups will be collected at before surgery, 1h and 25h after surgery, respectively and serum levels of TNF-alpha, IL-1 beta, CXCL8, IFN gamma and IL-4 at different time points will be measured. The primary outcome measures are serum TNF-alpha and IL-1 beta levels at 25h after surgery. The secondary outcome measures include serum levels of TNF-alpha, IL-1 beta, CXCL8, Th1/Th2 ratio (by calculating IFN gamma/IL-4) at 1h post surgery and serum levels of CXCL8, Th1/Th2 ratio at 25h post surgery.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Nonsmall Cell Lung Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Sham stimulation

Put the electrodes on SI3, SJ6, PC6 and LI4 without stimulation.

Group Type SHAM_COMPARATOR

Sham stimulation

Intervention Type PROCEDURE

Put electrodes on SI3, SJ6, PC6 and LI4 without stimulation

Treatment: Acupuncture stimulation

Stimulate the SI3, SJ6, PC6 and LI4 since 30 minutes before anesthesia induction until the end of operation. Stimulate again at above acupoints at 6 and 24h after operation, for 30 minutes each time. The stimulation frequency is 2/100Hz. The stimulation current is two to three times of the lowest current that the patient can feel.

Group Type EXPERIMENTAL

Acupuncture stimulation

Intervention Type PROCEDURE

Transcutaneous electrical acupoint stimulation on SI3, SJ6, PC6 and LI4

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Acupuncture stimulation

Transcutaneous electrical acupoint stimulation on SI3, SJ6, PC6 and LI4

Intervention Type PROCEDURE

Sham stimulation

Put electrodes on SI3, SJ6, PC6 and LI4 without stimulation

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients diagnosed Non-Small Cell Lung Carcinoma (NSCLC) and will have elective video-assisted thoracoscopic lobectomy surgery
* ASA grade 1-2
* BMI between 18 to 31 kg/m2

Exclusion Criteria

* with a history of thoracic surgery
* Unwilling to receive transcutaneous electrical acupoint stimulation
* BMI ≥ 32 kg/m2
* Infection or scars at the acupoints
* periphery nerve injury at the upper or lower limbs
* Severe liver, renal, brain or lung disease
* Drug abuse
* Patients who cannot coordinate with investigators, such as dysphasia，severe infectious disease and disturbance of consciousness
* Patients participating other trials

Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No